{"classes":[{"categories":[{"measurements":[{"comment":"NA = Median DOR was not reached (no progressive disease by time of last disease assessment).\n\nNA = DOR upper limit was not reached (no progressive disease by time of last disease assessment).","groupId":"OG000","lowerLimit":"25.2","upperLimit":"NA","value":"NA"},{"comment":"NA = Median DOR was not reached (no progressive disease by time of last disease assessment).\n\nNA = DOR upper and lower limits were not reached (no progressive disease by time of last disease assessment).","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"The DOR was defined, only for the subgroup of participants who achieved a CR or PR by investigator assessment, as the time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of PD or to death due to any cause, whichever comes first. CR is the disappearance of all evidence of disease and PR is the regression of measurable disease and no new sites. PD is the appearance any new lesion or increase by ≥ 50% of previously involved site from nadir. The analysis consisted of Kaplan-Meier estimates. DOR data was censored on the date of the last disease assessment documenting absence of PD for participants who did not have tumor progression and were still on study at the time of an analysis, were given antitumor treatment other than the study treatment, or were removed from study prior to documentation of tumor progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pembrolizumab 200 mg every 3 weeks (Q3W), intravenous infusion (IV) on Day 1 of each 3-week cycle for up to 35 administrations (approximately 2 years).","id":"OG000","title":"Pembrolizumab: Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)"},{"description":"Pembrolizumab 200 mg Q3W, IV on Day 1 of each 3-week cycle for up to 35 administrations (approximately 2 years).","id":"OG001","title":"Pembrolizumab: Relapsed or Refractory Richter Syndrome (rrRS)"}],"paramType":"MEDIAN","populationDescription":"The analysis population included all participants who received at least one dose of study medication (pembrolizumab) and who achieved a CR or PR by investigator assessment, as the time from start of the first documentation of objective tumor response (CR or PR).","reportingStatus":"POSTED","timeFrame":"Up to approximately 27 months (Database Cutoff Date: 28MAY2019)","title":"Duration of Response (DOR) Based on IWG Response Assessment Criteria by Investigator Assessment in Participants With Responses","type":"SECONDARY","unitOfMeasure":"Months"}